Top 6 Infectious Disease Therapeutics Market Worth $86.2 Billion by 2025: Grand View Research, Inc.

  Top 6 Infectious Disease Therapeutics Market Worth $86.2 Billion by 2025:
                          Grand View Research, Inc.

  PR Newswire

  SAN FRANCISCO, September 12, 2017

SAN FRANCISCO, September 12, 2017 /PRNewswire/ --

The global Top 6 Infectious Disease Therapeutics Market  is expected to reach
USD 86.2 billion by 2025, according to a new report by Grand View Research,
Inc. The market is primarily driven by increasing number of Human
Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis
cases globally.

     (Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )

Government and private organizations are investing heavily in the healthcare
sector to prevent, diagnose, and treat infectious diseases; rising investments
for development of new drugs to treat infectious diseases, and increasing
number of initiatives for creating awareness about these conditions are
expected to boost the market during the forecast period. Furthermore,
increasing number of patent expirations and entry of generic drugs in the
market are expected to increase the demand for infectious disease therapeutics
due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these
infections and free distribution of drugs by manufacturers in regions with
high incidence of these diseases are factors further expected to propel the
market growth. However, low penetration rate of anti-infective and
availability of large number of counterfeit drugs are expected to restraint
the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number
of manufacturers, favorable reimbursement scenario, and increasing healthcare
expenditure are major factors responsible for the largest share held by this
region. However, Asia Pacific is likely to grow at the highest rate between
2017 and 2025. High prevalence of infectious diseases; improving economic
conditions in Asian countries, rising government initiatives to increase the
adoption of treatments for infectious diseases, and rising funding activities
are factors that can be attributed for the highest growth rate of this region
during the forecast period.

Browse full research report with TOC on " Infectious Disease Therapeutics
Market Analysis By Disease Type (HIV infection, Influenza, Malaria,
Tuberculosis, Hepatitis, and HPV infection), By Region, And Segment Forecasts,
2014 - 2025 " at:
http://www.grandviewresearch.com/industry-analysis/infectious-disease-therapeutics-market

Further key findings from the report suggest:  

  * The HIV therapeutics segment held the largest revenue share in 2016 due to
    high number of HIV cases globally
  * North America dominated the global market owing to the strong
    reimbursement framework coupled with high adoption rate of treatments for
    infectious diseases
  * The HPV therapeutics segment is estimated to grow at the highest rate
    during the forecast period
  * Some of the key players are Novartis AG, Gilead, GlaxoSmithKline plc,
    Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst
    Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH

Browse related reports by Grand View Research:  

  * Hematology Analyzers and Reagents Market -
    http://www.grandviewresearch.com/industry-analysis/hematology-analyzers-and-reagents-market

  * Pediatric Interventional Cardiology Market -  
    http://www.grandviewresearch.com/industry-analysis/pediatric-interventional-cardiology-market

  * Online Patient Observation Market -
    http://www.grandviewresearch.com/industry-analysis/online-patient-observation-market

  * Surgical Imaging Market -
    http://www.grandviewresearch.com/industry-analysis/surgical-imaging-market

Grand View Research has segmented the top 6 infectious disease therapeutics
market on the basis of disease type and region:  

  * Disease Type Outlook (Revenue, USD Million, 2014 - 2025)  

       * HIV

            * Emtriva
            * Aptivus
            * Isentress
            * Lexiva/Telzir
            * Selzentry
            * Tivicay 
            * Atripla
            * Complera
            * Genvoya
            * Odefsey
            * Stribild
            * Truvada
            * Triumeq
            * Descovy
            * Vitekta
            * Others

       * Influenza

            * Relenza
            * Tamiflu 
            * Rapivab 
            * Others

       * TB

            * Sirturo
            * Others

       * Malaria

            * Coartem
            * Others

       * HPV
       * Hepatitis

  * Regional Outlook (Revenue, USD Million, 2014 - 2025)  

       * North America

            * U.S.
            * Canada

       * Europe

            * Germany
            * UK

       * Asia Pacific

            * China
            * Japan

       * Latin America

            * Brazil
            * Mexico

       * Middle East & Africa

            * South Africa

Read Our Blog By Grand View Research :
http://www.grandviewresearch.com/blogs/healthcare

About Grand View Research  

Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to
chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research,
Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email:
sales@grandviewresearch.com

Web: http://www.grandviewresearch.com
Press spacebar to pause and continue. Press esc to stop.